Enhancement of the immune response to non-replicating herpes simplex virus type-1 preparations by mucosal administration in the presence of cholera toxin

Vaccine

Volumn 15, Issue 10, 1997, Pages 1065-1069

  Richards, C M ^a   Hill, T J ^a   Williams, N A ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Cholera toxin; Herpes simplex virus; Mucosal immunization

Indexed keywords

CHOLERA TOXIN; HERPES VACCINE; VIRUS ANTIGEN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; HERPES SIMPLEX VIRUS 1; IMMUNE RESPONSE; INTRAGASTRIC DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; SKIN INFECTION; STRAIN DIFFERENCE; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION; VIRUS IMMUNITY; VIRUS INACTIVATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; CHOLERA TOXIN; GASTRIC MUCOSA; HERPESVIRUS 1, HUMAN; IMMUNITY, MUCOSAL; INJECTIONS, SUBCUTANEOUS; MALE; MICE; MICE, INBRED STRAINS; VACCINES, ATTENUATED; VIRAL VACCINES; VIRUS REPLICATION;

EID: 0030741194     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00010-8     Document Type: Article

References (34)

1. Stanberry, L.R. Herpes simplex virus vaccines as immunotherapeutic agents. Trends Microbiol. 1995, 3, 244-247.
2. Burke, R.L. Contemporary approaches to vaccination against herpes simplex virus. Curr. Top. Microbiol. Immunol. 1992, 179, 137-158.
3. Nash, A.A. and Cambouropoulos, P. The immune response to herpes simplex virus. Semin. Virol. 1993, 4, 181-186.
4. Mestecky, J., Mcghee, J.R., Arnold, R.R., Michalek, S.M., Prince, S.J. and Babb, J.L. Selective induction of an immune response in human external secretions by ingestion of bacterial antigen. J. Clin. Invest. 1978, 61, 731-737.
5. Tamura, S.I., Asanuma, H. and Ito, Y. et al. Formulation of inactivated influenza vaccines for providing effective cross-protection by intranasal vaccination in mice. Vaccine 1994, 12, 310-316.
6. McDermott, M.R. and Bienenstock, J. Evidence for a common mucosal immunologic system. J. Immunol. 1979, 122, 1892-1898.
7. Bowen, J.C., Alpar, H.O., Phillpotts, R. and Brown, M.R.W. Mucosal delivery of herpes simplex virus vaccines. Res. Virol. 1992, 143, 269-278.
8. Irie, H., Harada, Y. and Kataoka, M. et al. Efficacy of oral administration of live herpes simplex virus type 1 as a vaccine. J. Virol. 1992, 66, 2428-2434.
9. Irie, H., Shimeld, C., Williams, N. and Hill, T. Protection against ocular and cutaneous infection with herpes simplex virus type-1 by intragastric immunization with live virus. J. Gen. Virol. 1993, 74, 1357-1362.
10. Wu, H.Y. and Russell, M.W. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin-B subunit. Infect. Immunol. 1993, 61, 314-322.
11. Russell, M.W. and Wu, H.Y. Distribution, persistence, and recall of serum and salivary antibody responses to peroral immunization with protein antigen I/II of Streptococcus mutans coupled to the cholera toxin B subunit. Infect. Immunol. 1991, 59, 4061-4070.
12. Husband, A.J. Novel vaccination strategies for the control of mucosal infection. Vaccine 1993, 11, 107-112.
13. Wilson, A.D., Robinson, A., Irons, L. and Stokes, C.R. Adjuvant action of cholera toxin and pertussis toxin in the induction of IgA antibody response to orally administered antigen. Vaccine 1993, 11, 113-118.
14. Clarke, C.J., Wilson, A.D., Williams, N.A. and Stokes, C.R. Mucosal priming of T lymphocyte responses to fed protein antigens using cholera toxin as an adjuvant. Immunology 1991, 72, 323-329.
15. Bowen, J.C., Nair, S.K., Reddy, R. and Rouse, B.T. Cholera toxin acts as a potent adjuvant for the induction of cytotoxic T-lymphocyte responses with non-replicating antigens. Immunology 1994, 81, 338-342.
16. Hill, T.J., Field, H.J. and Blyth, W.A. Acute and recurrent infection with herpes simplex virus in the mouse: a model for studying latency and recurrent disease. J. Gen. Virol. 1975, 28, 341-353.
17. Efstathiou, S., Kemp, S., Darby, G. and Minson, A.C. The role of herpes simplex virus type 1 thymidine kinase in pathogenesis. J. Gen. Virol. 1989, 70, 869-879.
18. Jennings, R., Quasim, T., Sharrard, R.M., Hockley, D. and Potter, C.W. Zwitterionic detergent solubilisation of HSV-1 surface antigens. Arch. Virol. 1988, 98, 137-153.
19. Killington, R.A. and Powell, K.L. Growth, assay and purification of herpesviruses. In Virology a Practical Approach (Mahy, B.W.J., ed.) IRL Press, Oxford, 1985, pp. 207-236.
20. Erturk, M., Hill, T.J., Shimeld, C. and Jennings, R. Acute and latent infection of mice immunised with HSV-1 ISCOM vaccine. Arch. Virol. 1992, 125, 87-101.
21. Bailey, M., Williams, N.A., Wilson, A.D. and Stokes, C.R. Probit: weighted probit regression analysis. J. Immunol. Meth. 1992, 153, 261-262.
22. Waldman, R.H. and Ganguly, R. Immunity to infections on secretory surfaces. J. Infect. Dis. 1974, 130, 419.
23. Asanuma, H., Koide, F. and Suzuki, Y. et al. Cross-protection against influenza virus infection in mice vaccinated by combined nasal/subcutaneous administration. Vaccine 1995, 13, 3-5.
24. Muller, C.P., Beauverger, P., Schneider, F., Jung, G. and Brons, N.H.C. Cholera toxin B stimulates systemic neutral-izing antibodies after intranasal co-immunization with measles virus. J. Gen. Virol. 1995, 76, 1371-1380.
25. Takada, A. and Kida, H. Induction of protective antibody responses against pseudorabies virus by intranasal vaccination with glycoprotein B in mice. Arch. Virol. 1995, 140, 1629-1635.
26. Elson, C.O. Cholera toxin and its subunits as potential oral adjuvants. Curr. Top. Microbiol. Immunol. 1989, 146, 29-33.
27. Drew, M.D., Estrada-Correa, A., Underdown, B.J. and McDermott, M.R. Vaccination by cholera toxin conjugated to a herpes simplex type 2 glycoprotein D peptide. J. Gen. Virol. 1992, 73, 2357-2366.
28. Russell, M.W., Moldoveanu, Z., White, P.L., Sibert, G.J., Mestecky, J. and Michalek, S.M. Salivary, nasal, genital and systemic antibody responses in monkeys immunised intranasally with a bacterial protein antigen and the cholera toxin B subunit. Infect. Immunol. 1996, 64, 1272-1283.
29. Ghiasi, H., Nesburn, A.B. and Wechsler, S.L. Vaccination with a cocktail of seven recombinantly expressed HSV-1 glycoproteins protects against ocular HSV-1 challenge more efficiently than vaccination with any individual glycoprotein. Vaccine 1996, 14, 107-112.
30. Gallichan, W.S., Johnson, D.C., Graham, F.L. and Rosenthal, K.L. Mucosal immunity and protection after intranasal immunisation with recombinant adenovirus expressing herpes simplex virus glycoprotein B. J. Infect. Dis. 1993, 168, 622-629.
31. Gallichan, W.S. and Rosenthal, K.L. Specific secretory immune responses in the female genital tract following intranasal immunisation with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine 1995, 13, 1589-1595.
32. Ghiasi, H., Bahri, S., Nesburn, A.B. and Wechsler, S.L. Protection against herpes simplex virus-induced eye disease after vaccination with seven individually expressed herpes simplex 1 glycoproteins. Invest Opthalmol. Vis. Sci. 1995, 36, 1352-1360.
33. Lehner, T. Antigen presenting, contrasuppressor human T cefls. Immunol. Today 1986, 7, 87-92.
34. Nashar, T.O., Webb, H.M., Eaglestone, S., Williams, N.A. and Hirst, T.R. Potent immunogenicity of the B subunits of Escherichia coli heat-labile enterotoxin: receptor binding is essential and induces differential modulation of lymphocyte subsets. Proc. Natl Acad. Sci. USA 1996, 93, 226-230.